Accelr8 Announces Sale of OptiChem® Bio-Coatings License for Diagnostic Products
July 09 2010 - 2:26PM
Business Wire
Accelr8 Technology Corporation (NYSE Amex: AXK) today
announced that it completed the sale of a non-exclusive license for
its proprietary OptiChem® bio-coatings to an innovative, public
diagnostics company. The licensee is paying $1,865,000 over four
annual escalating payments and intends to use OptiChem® in its
disposable diagnostic devices.
According to David Howson, Accelr8’s president, “We are very
pleased to have a diagnostics innovator select OptiChem after
comparing a number of competing coatings. Once again, OptiChem
offered superior technical attributes that improve total system
performance at advantageous costs with scalable manufacturing.”
“The licensee’s products do not compete with our BACcel™ rapid
diagnostic system, but complement it in different applications.
This license expands our corporate presence in the clinical
diagnostic segment. It also opens future licensing opportunities
for additional, complementary new diagnostic applications that take
advantage of the optimization we’ve achieved with OptiChem’s
development,” he concluded.
About Accelr8
Accelr8 Technology Corporation (www.accelr8.com) is a developer of
innovative materials and instrumentation for advanced applications
in medical instrumentation, basic research, drug discovery, and
bio-detection. Accelr8 is developing a rapid analytical platform
for infectious pathogens, the BACcel™ system, based on its
innovative surface coatings, assay processing, and detection
technologies. In addition, Accelr8 licenses certain of its
proprietary technology for use in applications outside of Accelr8’s
own products.
Certain statements in this news release may be “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Statements regarding future prospects and
developments are based upon current expectations and involve
certain risks and uncertainties that could cause actual results and
developments to differ materially from the forward-looking
statement, including those detailed in the company's filings with
the Securities and Exchange Commission. Accelr8 does not undertake
an obligation to publicly update or revise any forward-looking
statements, whether as a result of new information or future
events.
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Accelerate Diagnostics, Inc. (American Stock Exchange): 0 recent articles
More Accelr8 Technology Corporation News Articles